Literature DB >> 34018072

The rosette-forming glioneuronal tumor mimicked cerebral cysticercosis: a case report.

Dan Zhu1, Ailan Cheng1, Nickita T L Benons2, Shuguang Chu3.   

Abstract

INTRODUCTION: Rosette-forming glioneuronal tumor (RGNT) is a rare variety of slow growing mixed glioneuronal tumor involving primarily fourth ventricular region. This is a comprehensive analysis of a 22-year-old woman with RGNT composed of mainly cystic components. In addition, the case showed multiple lesions located in brain parenchyma which mimicked cerebral cysticercosis. Here, we analyzed this case and listed some characteristics of RGNTs in reported literature which occurring in atypical locations for further understanding it. CASE REPORT: A 22-year-old woman presented with a history of transient dizziness, nausea, and vomiting. Magnetic resonance imaging (MRI) showed multiple cystic lesions in brain parenchyma and then the patient was diagnosed with cerebral cysticercosis possibility. Empirical anti-infective therapy in addition to a follow-up post 2 weeks of MRI examination showed the lesions unchanged. Finally, a biopsy of the right cerebellar hemisphere lesions verified RGNT.
CONCLUSION: RGNT is an uncommon tumor classified as grade I glioma by World Health Organization (WHO) with slightly longer course. The imaging findings of RGNT are not specific especially in atypical areas. RGNT is rare, but we should also consider the possibility in diagnosis and differential diagnosis.
© 2021. The Author(s).

Entities:  

Keywords:  Cerebral cysticercosis; Hemorrhage; Magnetic resonance imaging; Rosette-forming glioneuronal tumor

Mesh:

Year:  2021        PMID: 34018072      PMCID: PMC8443522          DOI: 10.1007/s10072-021-05199-x

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


Introduction

The rosette-forming glioneuronal tumor (RGNT) was first described by Komori et al. in 2002. As it was initially thought as dysembryoplastic neuroepithelial tumor (DNT) of the cerebellum [1]. In 2007, it was classified as grade I glioma by World Health Organization (WHO). RGNT occurs most often in young women with mean age of onset at 23.57 years [2]. There are few literatures regarding the imaging features and prognosis of RGNT. For most of the literatures on RGNT are case reports. RGNT is most commonly located in the fourth ventricle; however, recent reports demonstrated that RGNT can also occur at sites outside its usual locations. The lesions are mostly comprised of cystic-solid or solid, and the solid components present heterogenous enhancement. Here, we describe a rare case of a 22-year-old woman with RGNT in bilateral cerebellar hemisphere, brain stem, and left thalamus who was misdiagnosed as cerebral cysticercosis before biopsy.

Case report

A 22-year-old woman presented with a history of transient dizziness, nausea, and vomiting. No neurological deficits were apparent; however, on further evaluation, initially with computed tomography (CT) scan, revealed multiple cystic hypo-dense mass lesions in bilateral cerebellar hemisphere, brain stem, and left thalamus with unclear boundary (Fig. 1a–c). Magnetic resonance imaging (MRI) confirmed these lesions presented as hyper-intense in axial T2-weighted images and hypo-intense in axial T1-weighted images (Fig. 1d, e). The solid components were visible in some of the lesions in axial T2-weighted images (Fig. 1d). In addition, axial T2 FLAIR revealed iso-hyperintense (Fig. 1f). Diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) showed no restricted diffusion (Fig. 1g, h). After contrast, one of the tumors showed mild peripheral enhancement, while others presented no enhancement (Fig. 1i), and small nodule-like higher signals in T2-weighted images were present (Fig. 1d). While, on perfusion-weighted imaging, the lesions were hypo-perfused (Fig. 1j, k).
Fig. 1

a–c CT findings show the tumors in left thalamus, brain stem, and bilateral cerebellar hemisphere (red arrow). d–l MRI findings. The lesions in bilateral cerebellar hemisphere. d Hyper-intense in T2-weighted image and small nodule-like higher signal (red arrow) along with circled solid component. e Hypo-intense in T1-weighted image. f T2 flair image showed iso-hyper intense. g Hypo-intense in DWI. h Hyper-intense in ADC. i No obvious enhancement majority and minority presented as mild annular enhancement. j–k Perfusion-weighted imaging color map, decreased regional cerebral blood flow, and regional cerebral blood volume. l minor hemorrhage in the lesions. l SWI showed minor hemorrhage. m–o MRI findings for post 2 weeks. m–o Corresponding T1WI, T2 flair, and T1WI enhancement, no obvious changes compared with before

a–c CT findings show the tumors in left thalamus, brain stem, and bilateral cerebellar hemisphere (red arrow). d–l MRI findings. The lesions in bilateral cerebellar hemisphere. d Hyper-intense in T2-weighted image and small nodule-like higher signal (red arrow) along with circled solid component. e Hypo-intense in T1-weighted image. f T2 flair image showed iso-hyper intense. g Hypo-intense in DWI. h Hyper-intense in ADC. i No obvious enhancement majority and minority presented as mild annular enhancement. j–k Perfusion-weighted imaging color map, decreased regional cerebral blood flow, and regional cerebral blood volume. l minor hemorrhage in the lesions. l SWI showed minor hemorrhage. m–o MRI findings for post 2 weeks. m–o Corresponding T1WI, T2 flair, and T1WI enhancement, no obvious changes compared with before Based on the above radiological findings, the woman was initially diagnosed with cerebral cysticercosis most possibly. Naturally, primary tumors of the central nervous system and metastatic tumors were differential diagnoses. Subsequently, she was admitted to the infectious diseases department to conduct empirical anti-infective therapy in addition to a follow-up post 2 weeks of MRI examination. Over the course of 2 weeks, she underwent further laboratory examinations, including serologies (specifically enzyme-linked immunotransfer blots (EITBs)); however, the results were negative. Meanwhile, eosinophilic cells and lymphocytes were neither found in cerebrospinal fluid (CSF). Other parasite antibodies were not discovered either. Most importantly, there were no significant changes in the MRI findings after 15 days (Fig. 1m–o). Finally, to determine an ultimate diagnosis, she underwent a biopsy of the right cerebellar hemisphere lesions in which the histopathological results confirmed a WHO grade I RGNT ultimately. Microscopically, the tumors showed that small round nuclear tumor cells were distributed in a network and arranged into a chrysanthemum-shaped cluster surrounding the nerve with single permutation. Synaptophysin immunopositivity in the pericapillary area of a perivascular pseudorosette was shown, along with scattered neurons in the focal areas were also visible. In addition, glial fibrillary acidic protein (GFAP) in the astrocytic component of the tumor was diffuse distribution. (Fig. 2a–e).
Fig. 2

a–d Pathological pictures of the tumor. a Glioneuronal tumor with glial and neurocytic components. b Neurocytic rosette: small round nuclear tumor cells distributed in a network and a ring-like array of neurocytic tumor cell nuclei around an eosinophilic neuropil core (blue arrow) (hematoxylin-eosin: a×200; b×400). c, d Synaptophysin immunopositivity in the pericapillary area of a perivascular pseudorosette (red arrow) (c×200; d×400). Diffuse positivity for glial fibrillary acidic protein (GFAP) in the glial component of the tumor(e×200)

a–d Pathological pictures of the tumor. a Glioneuronal tumor with glial and neurocytic components. b Neurocytic rosette: small round nuclear tumor cells distributed in a network and a ring-like array of neurocytic tumor cell nuclei around an eosinophilic neuropil core (blue arrow) (hematoxylin-eosin: a×200; b×400). c, d Synaptophysin immunopositivity in the pericapillary area of a perivascular pseudorosette (red arrow) (c×200; d×400). Diffuse positivity for glial fibrillary acidic protein (GFAP) in the glial component of the tumor(e×200)

Discussion

RGNT is an unusual disease, and it is considered an independent entity of glioma, which is categorized as grade I by World Health Organization (WHO) due to its characteristics of containing both neural and glial components [3]. It is generally considered to be benign, but there have been reports that some can be invasive [4]. The disease was initially thought to only occur in the fourth ventricle, and the typical imaging characteristics are mid-line lesions which appeared in the fourth ventricle and extended to adjacent structures [5]. On MRI, RGNT typical imaging findings are relatively well circumscribed, with both solid and cystic components with T1-hypo-intense and T2-hyper-intense located in or around the fourth ventricle. Gadolinium-based contrast enhancement could show variable or no enhancement, but with increasing reports of the disease, other positions have also been reported, including the pineal region, pons, thalamus, spinal cord, optic chiasm, cerebellar hemisphere, optic pathway, lateral ventricle, septum pellucidum, cerebellar vermis, and even temporal lobe [6-9]. With regards to the English literature through a comprehensive search of Web of Science and PubMed using the search term “the rosette-forming glioneuronal tumor” nearly a decade, more than 100 articles have been published to date. After full text screening, excluding articles that were less relevant to the characteristics of RGNTs, nearly 70 articles were included by December 2020 finally. In general, 101 cases of RGNTs were reported located in the fourth ventricle, while 51 cases were located in atypical site. However, the imaging manifestations of RGNTs occurring outside the fourth ventricle are not specific; so, they are often misdiagnosed. Here, the characteristics of RGNTs located outside the fourth ventricle in 51 published cases were listed (Table 1). The lesions can be solid-cystic, cystic, or simple solid, and generally, the former is the most common. The average age of these published cases is 38 years old. Hemorrhage is rare in RGNTs, and only six cases presented positive for bleeding. Management of RGNTs has been accordant with the literatures. Surgery remains the primary treatment option, with gross total resection (GTR) recommended and subtotal resection (STR) as alternatives. The prognosis of RGNT is generally good, and recurrence is uncommon with a total of 4 cases recrudesced of the 51 cases. However, two patients died of these presented cases. Most of the tumors were single lesions with only 10 cases showed multiple lesions.
Table 1

Radiological presentation and characters of 51 cohort of patients

Author and yearLesionCase numberAge, sexLocationContrast enhancementT1WIT2WIHemorrhageManagementRecurrenceNumber of lesionsFollow-up
Pierre-Aurelien Beuriat et al., 2015Cystic113/FLeft cerebellar hemisphereNo enhancementHypoHyperNASTRNo1NA
Aaron Halfpenny et al., 2019Cystic25/FLeft temporal lobeNodular enhancementIso/hypoHyperNAGTRYes,10Y110Y
Lian Duan et al., 2017Cystic-solid326/FT9–11Heterogeneous enhancementHypoHyperNAGTRNo115M’
Lian Duan et al., 2017Cystic-solid435/FC3–7Partchy and inhomogeneousHypoHyperNAGTRNo117M’
Shuji Hamauchi et al., 2019Cystic-solid537/FC2–5Slight enhancementHypoHyperNAGTRNo12Y
Marc Eastin et al., 2016Cystic633/FRight thalamic, the ventricleNo enhancementHypoHyperNAGTRNo212M’
Adrien Collin et al., 2018Cystic-solid740/FC7–8Heterogeneous enhancingHypoHyperNAGTRNo16M’
Yazeed Al Krinawe et al., 2020Solid87/FSeptum pellucidumNo enhancementHypoHyperNASTRNo12Y
Bharadwaj, Rishab et al., 2020Cystic-solid912/MThe optic pathwayNo enhancementHypoHyperNABiopsyNo16M’
Fumine Tanaka et al., 2019Cystic-solid1018/MPonsPartial rim enhancementHypoHyperNABiopsyNo117Y
Emily P Sieg et al., 2016Cystic-solid118/FRight hypothalamusRing-like enhancementHypoHyperNASTRNo13Y
ArunkumarSekar et al., 2019Cystic-solid1216/MOptic chiasmRing-like enhancementHypoHyperNASTRNo1NA
Goutam Bera et al., 2017Cystic-solid1416/MLeft side of the vermisPatchy enhancementHypoHyperNAGTRNo11Y
Ji Xiong et al., 2012Cystic-solid1538/MSeptum pellucidum, the bilateral ventriclesHeterogeneous enhancementHypo-isoMainly hyperNASTRNo26M’
Kieren S.J. Allinson,2015Mainly cystic1633/MThe fourth ventricle, the third and lateral ventriclesPatchy enhancementHypoHyperNABiopsyProximately doubled in sizemultiple1Y
Noriko Sumitomo et al., 2017Cystic179/MThe right parietal lobeNo enhancementHypoHyperNASTRNo1NA
Caleb P. Wilson et al., 2020Cystic-solid1819/MLeft temporal, left gangliocapsular region, bilateral thalami, tectum, cerebellum.Slight enhancementHypoMildly hypeNASTRDramatic expansion, number increasingmultiple6Y
L.Gao et al., 2018Cystic1916/MCerebellar hemisphereSlight enhancementIso-hypoHypo-hyperNAGTRNA1NA
L.Gao et al., 2018Cystic2029/MLateral ventricleHeterogeneous enhancementIso-hypoHypo-hyperNAGTRNA1NA
L.Gao et al., 2018Cystic-solid2123/MCerebellar vermisHeterogeneous enhancementHypo-hyperHypo-hyperNASTRNA1NA
L.Gao et al., 2019Cystic2224/MLeft temporal lobeNo enhancementHypoHyperNAGTRNo1NA
L.Gao et al., 2019Cystic2330/MCerebellar vermisNo enhancementHypoHyperNAGTRNo1NA
Sajjad Muhammad et al., 2019Cystic-solid2422/NAPineal regionPartially and heterogeneous enhancementHypoHyperNASTRNo18W
Ibrahim Alnaami et al., 2013Solid2557/MThe posterior third ventricle.Heterogeneous enhancementIsoHyperNABiopsyNo16M’
Ibrahim Alnaami et al., 2013Cystic-soLid2628/MPosterior third ventricle extending into the aqueductNodular enhancementHypoHyperNABiopsyNo1NA
Özlem Yapıcıer et al., 2018Cystic2755/FMesial temporal lobeNo enhancementIso-hypoHeterogeneously hyperNAGTRNo1NA
H.Cebula et al., 2016Cystic-solid2875/FLeft posterior thalamicHeterogeneously hyperintenseHeterogeneously hypoHeterogeneously hyperIntralesional bleedingBiopsyNo progression11Y
Sonia García Cabezas et al., 2014Cystic-solid2924/MBoth cerebellar hemispheres, the left cerebellopontine angle, spinal cordIntense and heterogeneous enhancementIso-hypoHypo-hyperNABiopsyNoMultiple2Y
Shi-Yun Chen et al., 2016Cystic-solid3017/MRight basal gangliaHeterogeneous enhancementHypoHyperNASTRNo13Y
Shi-Yun Chen et al., 2017Cystic3133/MLeft parietal lobeNo enhancementHypoHyperNASTRNo13Y
Shi-Yun Chen et al., 2018Cystic-solid3221/FThe third and fourth ventricles and the suprasellar regionHeterogeneous enhancementHypoHyperNASTRDeadMultiple3Y
Yasutaka Fushimi et al., 2011Cystic-solid3328/FThe cerebellar vermisNo enhancementHypoHyperNASTRNo12Y
David Cachia et al., 2014Cystic3436/FRight frontal lobe, right midbrain tectum, and cerebellar vermisNo enhancementHypoHyperNASTRNoMultiple7M’
Philip GeorgeEye et al., 2017Cystic-solid3535/MThe third ventricleNo enhancementIsoHyperNASTRNA1NA
Orestes E. Solis et al., 2011Cystic-solid3616/FThe pineal gland regionNo enhancementIso-hypoHyperNASTRNo12M’
Ji Xiong et al., 2013Cystic3723/MLeft frontal lobeNo enhancementHypoHyperNAGTRNo18M’
Gorky Medhi et al., 2015Cystic-solid3832/MMidline posterior fossa, vermis and cerebellar hemispheresHeterogeneous enhancementIso-hypoHeterogeneously hyperYESSTRNoMultiple11M’
Gorky Medhi et al., 2015Cystic-solid3938/FPineal regionHeterogeneous enhancementIso-hypoHeterogeneously hyperYESSTRResidual lesions, stable13Y
Gorky Medhi et al., 2015Cystic-solid4024/MCerebellar hemispheres, vermis, midbrain, pons, medullaNo enhancementIso-hypoHeterogeneously hyperYESSTRResidual lesionsMultipleNA
Gorky Medhi et al., 2015Cystic4112/MPineal regionNo enhancementHypoHyperNOGTRResidual lesions13M’
Gorky Medhi et al., 2015Cystic-solid4240/FRight cerebellar hemisphere and vermisAnnular and nodular enhancementIso-hypoHeterogeneously hyperYESGTRMinimal residueMultiple4M’
S.Kemp et al., 2012Cystic4333/MLeft lateral ventricleNo enhancementHypoHyperNAGTRNA1NA
Ewa Matyja et al., 2014Cystic4422/MThe left temporal lobe.No enhancementHypoHyperNAGTRNo13.6Y
Junqing Xu et al., 2012Cystic-solid4539/MPineal gland, the third ventricleFaint heterogeneous contrast enhancementHypoIso-hyperNAGTRNoMultiple42M’
Benjamin Thurston et al., 2012Cystic-solid468/FLeft superior cerebellar peduncleHeterogeneous enhancementHypoHyperNAGTRYes, 9M19M’
Anil K. Mahavadi et al., 2020Cystic-solid4741/MThe third ventricleHeterogeneous enhancementMainly hypoMainly hyperNASTRResidual lesions, stable16M’
Pankaj Sharma et al., 2011Cystic-solid4816/FThe tectal region of the midbrainNo enhancementHypoHyperNABiopsyStable16M’
Pankaj Sharma et al., 2012Cystic-solid4917/MSuprasellar and interpeduncular cistern, the third ventriclePeripheral enhancementMainly hypoMainly hyperYESBiopsyStableMultipleNA
Seiji Yamada et al., 2019Cystic-solid5016/FRight temporal lobeMultinodular enhancementHypoHyperNAGTRNA1NA
Tanmoy Kumar Maiti et al., 2014Solid512/MThe posterior third ventricleNo enhancementHypoHyperNASTRDead113M’
Tanmoy Kumar Maiti et al., 2015Cystic-solid5212/MThe posterior third ventricleMild contrast enhancementHypoHyperNAGTRNo19M’

M man, F female, NA not available, GTR gross total resection, STR subtotal resection, iso iso-intensity, hypo hypo-intensity, hyper hyper-intensity, Y year, M’ month

Radiological presentation and characters of 51 cohort of patients M man, F female, NA not available, GTR gross total resection, STR subtotal resection, iso iso-intensity, hypo hypo-intensity, hyper hyper-intensity, Y year, M’ month In summary, the misdiagnosis in the above case reflects how RGNT is under-emphasized and poorly researched. Thus, based on the analysis of the present case and limited data available from review of literature, we propose that the following two aspects may have contributed significantly in misdiagnosing RGNT. Firstly, the case we highlighted occurred in the brain parenchyma, while more than 69.7% of previously reported RGNTs involve the fourth ventricle [3]. And multiple lesions involving the bilateral cerebellar hemisphere, brain stem, and left thalamus at the same time are rarely reported. Secondly, the imaging findings of this case overlapped with cerebral cysticercosis. As we all know, cerebral cysticercosis is the most common parasitic disease of the central nervous system (CNS). The imaging manifestations of the parenchymal active phase are multiple cystic lesions. The enhancement is not obvious and the hypo-perfusion on perfusion imaging. For the above reasons, the tumors were misdiagnosed as cerebral cysticercosis deservedly. Admittedly, there are distinct radiological signs which highlight uncertainties regarding the previous diagnosis: most notably include tiny spot-like hypo-intense in bilateral cerebellar hemisphere on the susceptibility weighted imaging (SWI) (Fig. 1l). After excluding tiny calcifications on CT (Fig. 1c), it can be assumed that there is minor hemorrhage within the lesions. Hemorrhage is almost invisible in cerebral cysticercosis, although there were also few reports of hemorrhages in RGNT. Two possible reasons may account for the latter. One being that the SWI sequence is rarely a routine sequence, and minor hemorrhages in many reported cases may go undetected because they are difficult to show on other sequences in MRI. On the other hand, it is generally assumed that RGNT is a benign tumor, microvascular proliferation is rare; therefore, the hemorrhages are infrequent as well. The evidence between microvascular endothelial proliferation and hemorrhages has been documented in RGNT [10, 11]. L. Gao et al. reported several cases of RGNTs with intratumoral hemorrhage in 2017. They summarized that intratumoral hemorrhage was one of the additional indications to the diagnosis of RGNT. Other indications included “green bell pepper sign,” CSF dissemination, and multiple satellite lesions. Medhi et al. also summed up that hemorrhage and CSF dissemination may be the characteristics of RGNT through the summary of 7 cases [12]. In our case, intratumoral hemorrhage and multiple satellite lesions are consistent with their conclusions. Therefore, the above signs may aid in diagnosing RGNTs. However, whether this microvascular proliferation and intratumoral hemorrhage are related to prognosis needs further research.

Conclusion

RGNT is an uncommon low-grade neuroglial tumor which is generally considered benign with slightly longer course [2]. Headache is the most recorded common symptom. Histopathologically, RGNT consists of two components: a neurocytic component that forms rosettes, and an astrocytic component that resembles a pilocytic astrocytoma [13]. Through the case we reported, we have discovered that RGNT can be multiple cystic lesions, and the brain parenchyma can be the major affected areas. The intratumoral hemorrhage shown by SWI sequence may have some significance for our diagnosis of it. In conclusion, RGNT often presents significant diagnostic dilemma, and hence, further knowledge of this tumor is essential as they are relatively slow growing and exhibit benign histological characteristics.
  13 in total

1.  Spontaneous modifications of contrast enhancement in childhood non-cerebellar pilocytic astrocytomas.

Authors:  Simona Gaudino; Francesca Quaglio; Chiara Schiarelli; Matia Martucci; Tommaso Tartaglione; Maria Rosaria Gualano; Giuseppe Maria Di Lella; Cesare Colosimo
Journal:  Neuroradiology       Date:  2012-09       Impact factor: 2.804

2.  Rosette-forming glioneuronal tumor of the fourth ventricle with advanced microvascular proliferation--a case report.

Authors:  Ewa Matyja; Wieslawa Grajkowska; Pawel Nauman; Artur Ozieblo; Wieslaw Bonicki
Journal:  Neuropathology       Date:  2010-11-24       Impact factor: 1.906

3.  Fourth ventricle rosette-forming glioneuronal tumor. Case report.

Authors:  Mahlon Johnson; John Pace; Judy F Burroughs
Journal:  J Neurosurg       Date:  2006-07       Impact factor: 5.115

4.  Rosette-Forming Glioneuronal Tumor of Spinal Cord.

Authors:  Adrien Collin; Homa Adle-Biassette; Augustin Lecler
Journal:  World Neurosurg       Date:  2018-08-16       Impact factor: 2.104

5.  A Multifocal Glioneuronal Tumor with RGNT-Like Morphology Occupying the Supratentorial Ventricular System and Infiltrating the Brain Parenchyma.

Authors:  Mauro Morassi; Oscar Vivaldi; Milena Cobelli; Barbara Liserre; Fausto Zorzi; Claudio Bnà
Journal:  World Neurosurg       Date:  2019-10-10       Impact factor: 2.104

6.  Rosette-Forming Glioneuronal Tumor in Opticochiasmatic Region-Novel Entity in New Location.

Authors:  Arunkumar Sekar; Satish Rudrappa; Swaroop Gopal; Nandita Ghosal; Abhishek Rai
Journal:  World Neurosurg       Date:  2019-02-18       Impact factor: 2.104

7.  Pediatric rosette-forming glioneuronal tumor of the septum pellucidum.

Authors:  Yazeed Al Krinawe; Majid Esmaeilzadeh; Christian Hartmann; Joachim K Krauss; Elvis J Hermann
Journal:  Childs Nerv Syst       Date:  2020-03-26       Impact factor: 1.475

8.  Histopathological, molecular, clinical and radiological characterization of rosette-forming glioneuronal tumor in the central nervous system.

Authors:  Chenlong Yang; Jingyi Fang; Guang Li; Shaowu Li; Tingting Ha; Jiangfei Wang; Bao Yang; Jun Yang; Yulun Xu
Journal:  Oncotarget       Date:  2017-11-24

9.  Spinal rosette-forming glioneuronal tumor: A case report.

Authors:  Shuji Hamauchi; Mishie Tanino; Kazutoshi Hida; Toru Sasamori; Shunsuke Yano; Shinya Tanaka
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

Review 10.  Rosette-forming glioneuronal tumor: an illustrative case and a systematic review.

Authors:  Caleb P Wilson; Arpan R Chakraborty; Panayiotis E Pelargos; Helen H Shi; Camille K Milton; Sarah Sung; Tressie McCoy; Jo Elle Peterson; Chad A Glenn
Journal:  Neurooncol Adv       Date:  2020-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.